BioVentrix Expands Heart Failure Treatment Portfolio with Acquisition of MateraCor, Inc.
Revolutionary Heart Failure Therapy Company Also Adds New Executive and [...]
BioVentrix Announces Raymond W. Cohen as Chairman of the Board and Newly Appointed Accredited Public Company Directors, Rinda K. Sama and Andrew G. Hinson to its Board of Directors
SAN RAMON, Calif. – July 21, 2021 – BioVentrix, Inc., [...]
BioVentrix Names Jim Dillon President and CEO
Proven Leader Will Take Revolutionary Heart Failure Therapy Company to [...]
Kardio-Tech-Firma aus Kalifornien gründet Deutschland-Niederlassung und macht so innovative Herztherapie breiter verfügbar
San Ramon, Kalifornien, und Hilden bei Düsseldorf, 19. Februar 2021„Bringing [...]
BioVentrix Receives 2021 NUB Status 1 Reimbursement Renewal in Germany for the Revivent TC™ TransCatheter Ventricular Enhancement System
SAN RAMON, Calif. – February 8, 2021 - BioVentrix, Inc., [...]
BioVentrix Announces Jerry Estep, MD, as Co-Principal Investigator for ALIVE Pivotal Trial Studying a Transcatheter Device for Heart Failure
SAN RAMON, Calif. – January 6, 2021 – BioVentrix, Inc., [...]
BioVentrix Announces the Appointment of Cardiac Device Veteran Chris Wolff as Vice President of U.S. Sales
San Ramon, CA, USA – October 5, 2020 – BioVentrix, [...]
Neuartige Herzoperation in Tübingen durchgeführt
Das Tübinger Herzzentrum hat nach einer Corona-bedingten Zwangspause erfolgreich einen [...]
Kasuistik zur Postinfarkt-Herzinsuffizienz publiziert
January 27, 2022 Erfolgreiches minimalinvasives Postmyokardinfarkt-Verfahren führt zu einem Anstieg [...]
BioVentrix Announces Pivotal ALIVE Trial Resumes with First Patients Treated with LIVE Therapy Since COVID-19 Pause
San Ramon, Calif. – September 2, 2020 – BioVentrix, Inc., [...]
